Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Rallybio Co. (NASDAQ:RLYB) has received an average rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.75.

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Rallybio in a research note on Tuesday, December 3rd.

Rallybio Stock Down 0.7 %

RLYB opened at $0.91 on Friday. The firm has a 50-day moving average price of $1.03 and a 200-day moving average price of $1.16. Rallybio has a twelve month low of $0.84 and a twelve month high of $3.46. The company has a market capitalization of $37.92 million, a price-to-earnings ratio of -0.57 and a beta of -1.55.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Hsbc Holdings PLC bought a new stake in shares of Rallybio during the 2nd quarter valued at about $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Rallybio in the second quarter valued at approximately $61,000. Acadian Asset Management LLC lifted its position in Rallybio by 116.3% during the second quarter. Acadian Asset Management LLC now owns 67,695 shares of the company’s stock valued at $89,000 after purchasing an additional 36,401 shares during the last quarter. Almitas Capital LLC purchased a new position in Rallybio in the 2nd quarter worth approximately $135,000. Finally, Geode Capital Management LLC increased its holdings in shares of Rallybio by 11.4% in the 3rd quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock worth $287,000 after buying an additional 24,980 shares during the last quarter. 90.34% of the stock is owned by institutional investors.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.